Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Press/Media: Research

Period	10 Dec 2019

Media contributions

Title	Urotoday
Country/Territory	United Kingdom
Date	10/12/2019
URL	https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/117659-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-with-dna-repair-gene-aberrations-toparp-b-a-multicentre-open-label-randomised-phase-2-trial.html
Persons	Suneil Jain